Clinical Trials Browser

Active not recruiting × Triple Negative Breast Neoplasms × Combined Modality Therapy × Clear all

NCT07018427 2025-06-12

Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms